Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland

Vaccine

Volumn 18, Issue 27, 2000, Pages 3106-3112

  Davidkin, Irja ^a   Peltola, Heikki ^b   Leinikki, Pauli ^a   Valle, Martti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antibody kinetics; Rubella antibodies; Two dose MMR vaccination

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FINLAND; FOLLOW UP; HUMAN; IMMUNITY; KINETICS; MAJOR CLINICAL STUDY; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; REVACCINATION; RUBELLA; VACCINATION;

EID: 0034662493     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00139-0     Document Type: Article

References (33)

1. Peltola H., Kurki T., Virtanen M., Nissinen M., Karanko V., Hukkanen V., et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet. 2:1986;137-139.
2. Peltola H., Heinonen O.P., Valle M., Paunio M., Virtanen M., Karanko V., Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two dose-vaccination program. N. Engl. J. Med. 331:1994;1397-1402.
3. Peltola H., Davidkin I., Valle M., Paunio M., Hovi T., Heinonen O.P., Leinikki P. No measles in Finland. Lancet. 350:1997;1364-1365.
4. Christenson B., Böttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine. 12:1994;41-45.
5. Böttiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine. 13:1995;1759-1762.
6. Chu S.Y., Bernier R.H., Stewart J.A., Herrmann K.L., Greenspan J.R., Henderson A.K., Liang A.P. Rubella antibody persistence after immunization. 16-year follow-up in the Hawaiian Islands. JAMA. 259:1988;3133-3136.
7. Herrmann K.L., Halstead S.B., Wiebenga N.H. Rubella antibody persistence after immunization. JAMA. 247:1982;193-196.
8. Hillary I.B., Griffith A.H. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine. 2:1984;274-276.
9. Just M., Just V., Berger R., Burkhardt F., Schilt U. Duration of immunity after rubella vaccination: a long-term study in Switzerland. Rev. Infect. Dis. 7:1985;S91-S94.
10. O'Shea S., Best J.M., Banatvala J.E., Marshall W.C, Dudgeon J.A. Persistence of rubella antibody 8-18 years after vaccination. Br. Med. J. 288:1984;1043.
11. O'Shea S., Woodward S., Best J.M., Banatvala J.E., Holzwl H., Dudgeon J.A. Rubella vaccination: persistence of antibodies for 10-21 years. Lancet. 2:1988;909.
12. Väänänen P., Vaheri A. Haemolysis-in-gel test in immunity surveys and diagnosis of rubella. J. Med. Virol. 3:1979;245-252.
13. Best J.M. Rubella vaccines: past, present and future. Epidemiol. Infect. 107:1991;17-30.
14. Boulianne N., De Serres, G., Ratnam S., Ward B.J., Joly J.R., Duval B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine. 13:1995;1611-1616.
15. Christenson B., Böttiger M., Heller L. Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br. Med. J. 287:1983;389-391.
16. Miller E., Hill A., Morgan-Capner P., Forsey T., Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 13:1995;799-802.
17. Johnson C.E., Kumar M.L., Whitwell J.K., Staehle B.O., Rome L.P., Dinakar C., Hurni W., Nalin D.R. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given to six vs. eleven to thirteen years. Pediatr. Infect. Dis. J. 15:(8):1996;687-692.
18. Böttiger M., Forsgren M. 20-years' experience of rubella vaccination in Sweden: 10 years' of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine. 15:1997;1538-1544.
19. Davidkin I., Valle M., Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine. 13:(16):1995;1617-1622.
20. Davidkin I., Valle M. Vaccine induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine. A twelve-year follow-up in two cohorts. Vaccine. 16:(20):1998;2052-2857.
21. Ukkonen P., von Bonsdorff C.-H. Rubella immunity and morbidity: effects of vaccination in Finland. Scand. J. Infect. Dis. 20:1988;255-259.
22. O'Shea S., Best J.M., Banatvala J.E. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J. Infect. Dis. 148:1983;639-647.
23. Serdula M.K., Halstead S.B., Wiebenga N.H., Herrmann K.L. Serological response to rubella revaccination. JAMA. 251:1984;1974-1977.
24. Horstmann D.M., Schleuderberg A., Emmons J.E, Evans B.K., Randolph M.F., Andiman W.A. Persistence of vaccine-induced immune responses to rubella comparison with natural infection. Rev. Infect. Dis. 7:(Suppl.):1985;580-585.
25. Rossier E., Phipps P.H., Polley J.R., Webb T. Absence of cell-mediated immunity to rubella virus 5 years after rubella vaccination. Can. Med. Assoc. J. 116:1977;481-484.
26. Rossier E., Phipps P.H, Weber J.M, Meurman O.H. Persistence of humoral and cell-mediated immunity to rubella virus in cloistered nuns and in schoolteachers. J. Infect. Dis. 144:1981;137-141.
27. Cusi M.G., Rossolini G.M., Valensin P.E., Cellesi C., Zanchi A. Serological evidence of reinfection among vaccinees during rubella outbreak. Lancet. 336:1990;1071.
28. Cusi M.G., Valensin P.E., Cellesi C. Possibility of reinfection after immunisation with RA 27/3 live attenuated rubella virus. Arch. Virol. 129:1993;337-340.
29. Matter L., Kogelschatz K., Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J. Infect. Dis. 175:1997;749-755.
30. Forsgren M., Sörén L. Subclinical rubella reinfection in vaccinated women with rubella-specific IgM response during pregnancy and transmission of virus to the fetus. Scand. J. Infect. Dis. 17:1985;337-341.
31. Hornsten L., Levy U., Fogel A. Clinical rubella with transmission to the fetus in a pregnant woman considered to be immune. N. Engl. J. Med. 391:1988;1415-1416.
32. Skendzel L.P. Rubella immunity: defining the level of protective antibody. Am. J. Clin. Pathol. 106:1996;170-174.
33. Ukkonen P. Rubella immunity and morbidity: impact of different vaccination programs in Finland. Scand. J. Infect. Dis. 28:1996;31-35.